SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Edderd who wrote (5880)3/12/1998 7:37:00 AM
From: blankmind  Read Replies (2) | Respond to of 23519
 
You make some good points.

Here's mine:

1. The ED market will be in the billions of dollars.

2. Vivus will hold at least 20 to 30% - even if viagra (which hasn't even been approved yet) - is successful

3. Vivus' 20 to 30% will equat in to $300 - $400 mill per year in revenues - which would be about triple what vivus did last year. Hence - $3 a share in profts - hence - a stock that should be over $40.

4. Time will tell. Shorts are toast. Just my thoughts.

Out.



To: Edderd who wrote (5880)3/14/1998 10:18:00 PM
From: Brian Malloy  Read Replies (1) | Respond to of 23519
 
As for mixing Muse and Viagra, one would hope they do it under a doctor's supervision initially - otherwise, we are going to hear about a lot of people with orthostatic hypotension or priapism.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News